{"entity":{"id":"mgmt","kind":"term","name":"MGMT promoter methylation","aka":[],"tldr":"A chemical switch that turns off a DNA-repair gene. When it is off, temozolomide works much better.","summary":"O6-methylguanine-DNA methyltransferase repairs the lesion temozolomide creates; promoter methylation silences it in ~40% of glioblastomas. Methylated: median OS ~23 months with chemoradiation; unmethylated: ~13 months with minimal temozolomide benefit, so unmethylated patients are the priority for novel-agent trials (e.g., CheckMate 498, which failed). Assay (MSP, pyrosequencing, methylation array) and cut-off variability persist.","asOf":"2026-09-06","wikipedia":"https://en.wikipedia.org/wiki/O-6-methylguanine-DNA_methyltransferase","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/O-6-methylguanine-DNA_methyltransferase"}],"tags":[],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["methylation-profiling"],"targets":[],"drugs":["temozolomide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Biomarkers"},"route":"/terms/mgmt/","neighbours":{"cancer":[{"id":"idh-mutant-astrocytoma","kind":"cancer","name":"Astrocytoma, IDH-mutant (grades 2 to 4)","route":"/cancers/idh-mutant-astrocytoma/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"pituitary-tumours","kind":"cancer","name":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","route":"/cancers/pituitary-tumours/"}],"technology":[{"id":"methylation-profiling","kind":"technology","name":"DNA methylation profiling","route":"/technologies/methylation-profiling/"}],"drug":[{"id":"capecitabine-temozolomide","kind":"drug","name":"Capecitabine + temozolomide (CAPTEM)","route":"/drugs/capecitabine-temozolomide/"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"trial":[{"id":"cctg-ce6","kind":"trial","name":"CCTG CE.6 / EORTC 26062-22061 (Perry trial)","route":"/trials/cctg-ce6/"},{"id":"checkmate-498","kind":"trial","name":"CheckMate 498","route":"/trials/checkmate-498/"},{"id":"checkmate-548","kind":"trial","name":"CheckMate 548","route":"/trials/checkmate-548/"},{"id":"eortc-26981","kind":"trial","name":"EORTC 26981 / NCIC CE.3 (Stupp trial)","route":"/trials/eortc-26981/"}],"bottleneck":[{"id":"b-brain-delivery","kind":"bottleneck","name":"The brain: barrier and sanctuary","route":"/bottlenecks/b-brain-delivery/"}],"pathway":[{"id":"base-excision-repair-parp","kind":"pathway","name":"Base excision repair, PARP & alkylation damage","route":"/pathways/base-excision-repair-parp/"},{"id":"epigenetic-reprogramming","kind":"pathway","name":"Epigenetic reprogramming","route":"/pathways/epigenetic-reprogramming/"},{"id":"mutagenesis-signatures","kind":"pathway","name":"Mutagenesis & mutational signatures","route":"/pathways/mutagenesis-signatures/"},{"id":"blood-brain-barrier-metastasis","kind":"pathway","name":"The blood-brain barrier & brain metastasis","route":"/pathways/blood-brain-barrier-metastasis/"}],"collection":[{"id":"national-brain-tumor-society","kind":"collection","name":"National Brain Tumor Society (NBTS)","route":"/collections/national-brain-tumor-society/"}],"term":[{"id":"1p19q-codeletion","kind":"term","name":"1p/19q codeletion","route":"/terms/1p19q-codeletion/"},{"id":"methylation-arrays","kind":"term","name":"DNA methylation arrays and beta values (450k, EPIC)","route":"/terms/methylation-arrays/"},{"id":"sdh-deficiency","kind":"term","name":"SDH deficiency (SDHB immunohistochemistry loss)","route":"/terms/sdh-deficiency/"}],"target":[{"id":"mgmt-protein","kind":"target","name":"MGMT (O6-methylguanine-DNA methyltransferase)","route":"/targets/mgmt-protein/"}],"biomarker":[{"id":"mgmt-promoter-methylation","kind":"biomarker","name":"MGMT promoter methylation","route":"/biomarkers/mgmt-promoter-methylation/"}]}}